title: The potential impact of adding genetic markers to clinical parameters in managing high-risk prostate cancer patients.
abstract: OBJECTIVE
  High-risk prostate cancer is a potentially lethal disease that is increasing in the diagnosis of prostate cancer patients. Compared to other prostate cancer patients (medium or low risk), management, diagnosis and treatment are not as successful among high-risk patients. Because the genetic characterization of prostate cancer patients is increasing, we aimed to determine whether genetic information in one of the primary associated genes, such as RNASEL (2', 5'-oligoadenylate-dependent RNase L), could be used as a biomarker to improve the quality of life and treatment among high-risk patients. The main objective is to identify genetic variants of RNASEL that could be associated with high-risk prostate cancer to improve the clinical managing of these patients.
  
  
  METHODS
  A total of 231 prostate cancer patients were genotyped for 7 variants of RNASEL gene. Clinical information was obtained from medical examinations and genetic analysis (amplification and sequencing 7 variants of RNASEL gene) were performed by the researchers. Data were processed by statistical analysis (Chi square and logistic regression) using SPSS v.15.0.
  
  
  RESULTS
  Comparisons between genotypes and clinical characteristics of patients revealed that individuals with GG in D541E, AA in R462Q and AG in I97L in RNASEL gene were high-risk patients according to the European Urology Guidelines.
  
  
  CONCLUSIONS
  Genotyping the RNASEL gene with routine diagnostic techniques could confer a more precise diagnosis of high-risk prostate cancer patients and increase the diagnostic accuracy above the current rate of 70% due to the relation between the genetic variants of RNASEL gene and the risk of this cancer.
authors.affiliation: Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Facultad de Medicina, Universidad de Granada, Avda.de Madrid, 11, 18071 Granada, Spain ; Center GENYO (Pfizer-University of Granada-Andalusian Government Center for Genomics and Oncological Research), Granada, Spain.
authors.forename: Maria Jesus
authors.initials: MJ
authors.lastname: Alvarez-Cubero
authors.forename: Luis Javier
authors.initials: LJ
authors.lastname: Martinez-Gonzalez
authors.forename: Fernando
authors.initials: F
authors.lastname: Vazquez-Alonso
authors.forename: Maria
authors.initials: M
authors.lastname: Saiz
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Alvarez
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Lorente
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: Cozar
keywords: Biomarkers; High risk; Prostate cancer; RNASEL gene; Staging; Treatment
references.citation: J Urol. 2005 Dec;174(6):2158-63
references.pmid: 16280755
references.citation: J Clin Oncol. 2011 May 20;29(15):2040-5
references.pmid: 21502546
references.citation: Eur Urol. 2012 Jun;61(6):1096-106
references.pmid: 22386839
references.citation: MAGMA. 2008 Nov;21(6):371-7
references.pmid: 18751745
references.citation: J Urol. 1997 Mar;157(3):902-6
references.pmid: 9072596
references.citation: BJU Int. 2007 Jun;99(6):1421-6
references.pmid: 17355373
references.citation: Mol Ecol Resour. 2010 May;10(3):564-7
references.pmid: 21565059
references.citation: Radiology. 2000 May;215(2):445-51
references.pmid: 10796923
references.citation: Adv Urol. 2012;2012:641689
references.pmid: 22110494
references.citation: JAMA. 2008 Jan 23;299(3):289-95
references.pmid: 18212313
references.citation: Nat Genet. 2002 Dec;32(4):581-3
references.pmid: 12415269
references.citation: Clin Cancer Res. 2007 Oct 1;13(19):5959-64
references.pmid: 17908993
references.citation: Carcinogenesis. 2010 Sep;31(9):1597-603
references.pmid: 20576793
references.citation: Prostate Cancer Prostatic Dis. 2012 Jun;15(2):144-9
references.pmid: 22083266
references.citation: Prostate. 2010 Nov 1;70(15):1716-27
references.pmid: 20564318